FrançaisAre analysts right about Integra Lifesciences Holdings (IART)?
📈 See the interactive version (live chart) →
Historical analyst accuracy
For Integra Lifesciences Holdings, we replayed every analyst price target of the past 12 months and measured the real outcome: 56% were profitable, average return +11% (75 calls). At 3 months: -3% average return (34% profitable). The higher the %, the more often analysts were right on this stock.
Most reliable analysts on this stock (past track record)
Their past track record on this stock (targets replayed against real prices) — not a forecast of what will happen.
| Analyst / broker | Calls i | % profitable i | Avg return i |
|---|---|---|---|
| JMP Securities | 14 | 7% | -19% |
| Credit Suisse | 8 | 62% | +17% |
| Jefferies | 6 | 33% | +2% |
| B of A Securities | 6 | 67% | +16% |
| Citigroup | 6 | 100% | +36% |
Frequently asked questions
Is Integra Lifesciences Holdings a buy right now?
The analyst consensus on Integra Lifesciences Holdings (IART) is "Hold" (0 bullish, 5 bearish calls over 12 months). This is not advice: historically, 56% of their targets on this stock turned out profitable over 1 year.
What is Integra Lifesciences Holdings's price target?
The median 12-month price target is $19.00 (+13% vs $16.85), ranging from $18.00 to $19.00 (5 analysts).
Are analysts accurate on Integra Lifesciences Holdings?
Over 1 year, 56% of analyst targets on Integra Lifesciences Holdings were profitable, for an average return of +11% (across 75 timestamped calls). This is JPI Invest's accuracy metric.
What is the Integra Lifesciences Holdings stock forecast?
Analysts target a median of $19.00 within 12 months, i.e. +13% vs the current price. The most bullish targets $19.00, the most cautious $18.00.
What is the Integra Lifesciences Holdings stock forecast for 2026 or long term (2030)?
Note: analyst targets are 12-month (median $19.00, +13%), NOT 2030. No reliable 5-10 year price forecast exists (« 2030 prediction » models are speculative). The most useful inputs: the 12-month median above, these analysts' historical accuracy (56%), and the stock's past trajectory.
Is Integra Lifesciences Holdings overvalued?
Detailed valuation data for Integra Lifesciences Holdings is available in the interactive analysis.
📊 See the full interactive analysis of Integra Lifesciences Holdings →
What is JPI Invest?
JPI Invest aggregates analyst recommendations across the entire S&P 500 (plus the S&P MidCap 400), replays them against real prices and measures who predicts best — on results, not reputation. Instead of taking a price target at face value, you see each analyst's track record on each stock.
- 🏆 Analyst leaderboard by real reliability (beating their sector, not just riding the rally)
- 🎯 What to buy: 3 backtested methods over 6 years, from cautious to aggressive
- 💬 AI assistant: ask anything about any stock, with the numbers
- 📊 Portfolio tracking + 🔔 price alerts by email
⚠️ Educational information, not investment advice. Analyst price targets are 12-month and can be wrong. Data via Yahoo Finance, recomputed by JPI Invest.